Q5121Inj. avsola, 10 mg

Published CMS Medicare Part B payment-limit context for Q5121, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.

CMS payment limit

$30.83

per 10 MG · Medicare Part B

Up 10.0%from $28.04 in 2026-Q2

Current quarter: 2026-Q3FinalEffective July 1, 2026
Billing unit: 10 MG

Payment limit over time

$32.3813$18.1977

2024-Q4: $21.29; 2025-Q1: $19.825; 2025-Q2: $19.749; 2025-Q3: $20.886; 2025-Q4: $20.405; 2026-Q1: $23.811; 2026-Q2: $28.04; 2026-Q3: $30.83

No current FDA shortage matchThe latest completed FDA data has no affected record matching the Infliximab ingredient family (FDA data as of August 20, 2026).

Email me when FDA shortage status changes

Avsola

Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.

Other Infliximab presentations

2 other CMS codes

Source-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.

Swipe to see all columns

HCPCS	CMS description	Current quarter 2026-Q3	Prior quarter 2026-Q2	Change	NDCs	View history
J1745	Infliximab not biosimil 10mg	$31.479 per 10 MG	$31.041 per 10 MG	Up 1.4%
Q5103	Injection, inflectra	$27.71 per 10 MG	$26.035 per 10 MG	Up 6.4%

Email me when a new presentation appears

Put another code on your radar.

Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.

Explore CMS codes